Abuse potential of zomepirac.
Zomepirac sodium, a nonsteroidal anti-inflammatory analgesic, was compared to morphine sulfate and placebo in an abuse liability study in a postaddiction population. Morphine (15 and 30 mg), but not zomepirac (400 and 800 mg), induced pupillary constriction and characteristic morphinelike subjective effects. The 800-mg dose of zomepirac was discriminated but was not euphorigenic. This study indicates that zomepirac is not likely to be abused.
D001794:Blood Pressure / Q000187:drug effects; D004341:Drug Evaluation; D005059:Euphoria; D006801:Humans; D009020:Morphine / Q000494:pharmacology; D011680:Pupil / Q000187:drug effects; D011758:Pyrroles / Q000494:pharmacology*; D019966:Substance-Related Disorders; D011795:Surveys and Questionnaires; D014046:Tolmetin / Q000031:analogs & derivatives / Q000494:pharmacology*
D011758:Pyrroles; D009020:Morphine; C020549:zomepirac; D014046:Tolmetin